
Date: 1/4/2021
Nomination Number: 0936

Purpose: This document summarizes the information addressing a nomination submitted on July 17, 2020 through the Effective Health Care Website. This information was used to inform the Evidence-based Practice Center (EPC) Program decisions about whether to produce an evidence report on the topic, and if so, what type of evidence report would be most suitable.

Issue: Insurance prior authorization (PA) is a health-plan cost-control measure that requires healthcare providers to obtain advanced approval from insurance companies before a specific service or treatment is delivered to a patient to qualify for coverage.1 The nominator for this topic sought to understand the impact of this practice on patient healthcare and its general impact on clinicians, providers, and healthcare systems, in the area of post-acute rehabilitation.

Program Decision:
The EPC Program will not develop a new evidence review because we did not find enough primary studies addressing the concerns of this nomination.

Key Findings
• We did not find any existing evidence to address the nomination.

Background
According to the American Medical Association (AMA), insurance prior authorization (PA), which is also known as prior approval, is a “health plan cost-control process by which physicians and other healthcare providers must obtain advance approval from a health plan before a specific service is delivered to the patient to qualify for payment coverage.”1 The primary rationale behind the use of prior authorization is to help control health care costs without negatively impacting health outcomes. However, the impact of prior authorization is not fully understood.2

An important consideration is the potential impact of PA on healthcare delivery.2 A 2019 AMA survey of physicians regarding PA found that 74 percent reported that it led to patients abandoning treatment, 90 percent perceived that negative outcomes were associated with it, 24 percent reported patient adverse outcomes associated with it, and 16 percent reported a hospital admission associated with it.3

The AMA identifies PA as an issue to be addressed nationally, describing it as a process that comes between a physician and patient’s care, costs physicians valuable time, undermines physician expertise, and “doesn’t put patients first.”4 Congress has also recognized some of these concerns, and secured funding to study the impact of such PA on patient health in May 2019.5
The nominators for this topic are specifically interested in the benefits and harms of PA for post-acute rehabilitation on healthcare outcomes, clinicians and administrators, and healthcare systems. Post-acute hospital rehabilitation is a high-cost area of healthcare, and, as such, is an area where there may be motivation to cut costs through measures such as PA. 6

**Scope**

1. What are the benefits and harms of insurance prior authorization (PA) requirements for post-acute rehabilitation on patient healthcare outcomes?
   a. How do patient characteristics (diagnosis and severity, age, sex, race, education, socioeconomic status, care for which PA is sought) influence patient health outcomes?
   b. How do features of the insurance PA process (e.g. paper, electronic, phone, clinical pathways, limited authorization operating hours, etc.) influence patient health outcomes?
2. What are the benefits and harms of insurance PA requirement for post-acute rehabilitation on clinicians and administrative staff?
   a. How do provider characteristics (physician, practice size, facility, expertise, staff experience, geographic location, etc.) influence clinical and administrative staff outcomes?
   b. How do features of the insurance PA process (e.g. paper, electronic, phone, clinical pathways, limited authorization operating hours, etc.) influence clinical and administrative staff outcomes?
3. What are the benefits and harms of insurance PA for post-acute rehabilitation on healthcare systems?
   a. How do features of the healthcare system (size, single payer versus fee for service versus other insurance structures, etc.) influence health system related outcomes.
   b. How do features of the PA process (e.g. paper, electronic, phone, clinical pathways, limited authorization operating hours, etc.) influence health system related outcomes?

**Table 1. Questions and PICOs**

<table>
<thead>
<tr>
<th>Questions</th>
<th>1. Benefits and harms of insurance PA for post-acute rehabilitation on patient healthcare outcomes</th>
<th>2. Benefits and harms of insurance PA for post-acute rehabilitation on clinicians and administrative staff</th>
<th>3. Benefits and harms of insurance PA for post-acute rehabilitation on healthcare systems</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Adults seeking post-acute rehabilitation treatment</td>
<td>Clinicians and administrative staff who provide post-acute rehabilitation services</td>
<td>Healthcare systems that provide post-acute rehabilitation services</td>
</tr>
<tr>
<td>Interventions</td>
<td>Any</td>
<td>Any</td>
<td>Any</td>
</tr>
<tr>
<td>Comparators</td>
<td>Any</td>
<td>Any</td>
<td>Any</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Healthcare outcomes</td>
<td>Clinical and administrative staff outcomes</td>
<td>Health-system related outcomes</td>
</tr>
</tbody>
</table>

Abbreviations: PA=prior authorization; PICOS= population, intervention, comparator, outcome, setting.

**Assessment Methods**

See Appendix A.
Summary of Literature Findings

We did not find any systematic reviews or primary studies addressing the key questions (KQs).

Table 2. Literature identified for each KQ

<table>
<thead>
<tr>
<th>Question</th>
<th>Systematic reviews (12/2017-12/2020)</th>
<th>Primary studies (12/2015-12/2020)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Question 1: PA patient healthcare outcomes</td>
<td>Total: 0</td>
<td>Total: 0</td>
</tr>
<tr>
<td>Question 2: PA and clinical and administrative outcomes</td>
<td>Total: 0</td>
<td>Total: 0</td>
</tr>
<tr>
<td>Question 3: PA and health system outcomes</td>
<td>Total: 0</td>
<td>Total: 0</td>
</tr>
</tbody>
</table>

Abbreviations: KQ=key question.

See Appendix B for detailed assessments of all EPC selection criteria.

Summary of Selection Criteria Assessment

We did not find any existing evidence synthesis products or primary studies addressing the nomination.

Please see Appendix B for detailed assessments of individual EPC Program selection criteria.

References

Author
Lisa Winterbottom
Emily Gean
Charli Armstrong

Conflict of Interest: None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

Acknowledgements
Kelly Vander Ley
Mark Helfand
Christine Chang

This report was developed by the Scientific Resource Center under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290-2017-00003C). The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or of the U.S. Department of Health and Human Services.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact EPC@ahrq.hhs.gov.
Appendix A: Methods

We assessed nomination for priority for a systematic review or other AHRQ Effective Health Care report with a hierarchical process using established selection criteria. Assessment of each criteria determined the need to evaluate the next one. See Appendix B for detailed description of the criteria.

Appropriateness and Importance
We assessed the nomination for appropriateness and importance.

Desirability of New Review/Absence of Duplication
We searched for high-quality, completed or in-process evidence reviews published in the last three years December 3, 2017 - December 3, 2020 on the questions of the nomination from these sources:

- AHRQ: Evidence reports and technology assessments
  - EHC Program https://effectivehealthcare.ahrq.gov/
  - AHRQ Technology Assessment Program https://www.ahrq.gov/research/findings/ta/index.html
- US Department of Veterans Affairs Products publications
  - Evidence Synthesis Program https://www.hsrd.research.va.gov/publications/esp/
  - VA/Department of Defense Evidence-Based Clinical Practice Guideline Program https://www.healthquality.va.gov/
- Cochrane Systematic Reviews https://www.cochranelibrary.com/
- PROSPERO Database (international prospective register of systematic reviews and protocols) http://www.crd.york.ac.uk/prospero/
- PDQ-Evidence https://www.pdq-evidence.org/
- Epistemonikos https://www.epistemonikos.org/
- Health System Evidence https://www.healthsystemevidence.org/

Impact of a New Evidence Review
The impact of a new evidence review was qualitatively assessed by analyzing the current standard of care, the existence of potential knowledge gaps, and practice variation. We considered whether it was possible for this review to influence the current state of practice through various dissemination pathways (practice recommendation, clinical guidelines, etc.).

Feasibility of New Evidence Review
We conducted a limited literature search in PubMed from the last five years December 3, 2015 - December 3, 2020.

Search strategy
### Appendix B. Selection Criteria Assessment

<table>
<thead>
<tr>
<th>Selection Criteria</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Appropriateness</td>
<td></td>
</tr>
<tr>
<td>1a. Does the nomination represent a health care drug, intervention, device, technology, or health care system/setting available (or soon to be available) in the United States?</td>
<td>Yes</td>
</tr>
<tr>
<td>1b. Is the nomination a request for an evidence report?</td>
<td>Yes</td>
</tr>
<tr>
<td>1c. Is the focus on effectiveness or comparative effectiveness?</td>
<td>Yes</td>
</tr>
<tr>
<td>1d. Is the nomination focus supported by a logic model or biologic plausibility? Is it consistent or coherent with what is known about the topic?</td>
<td>Yes</td>
</tr>
<tr>
<td>2. Importance</td>
<td></td>
</tr>
<tr>
<td>2a. Represents a significant disease burden; large proportion of the population</td>
<td>Yes. In 2016, there were 28,900 residential care communities in the United States, with a total of 996,100 beds and 811,500 residents. The AMA describes PA as a burdensome process that impacts both physicians and patients.</td>
</tr>
<tr>
<td>2b. Is of high public interest; affects health care decision making, outcomes, or costs for a large proportion of the United States population or for a vulnerable population</td>
<td>Yes. In 2016, there were 28,900 residential care communities in the United States, with a total of 996,100 beds and 811,500 residents. The AMA describes PA as a burdensome process that impacts both physicians and patients.</td>
</tr>
<tr>
<td>2c. Incorporates issues around both clinical benefits and potential clinical harms</td>
<td>Yes</td>
</tr>
<tr>
<td>2d. Represents high costs due to common use, high unit costs, or high associated costs to consumers, to patients, to health care systems, or to payers</td>
<td>Yes. In 2015, Medicare spending on post-acute care was $60.3 billion, which was 10% of the total national health care spending.</td>
</tr>
<tr>
<td>3. Desirability of a New Evidence Review/Absence of Duplication</td>
<td></td>
</tr>
<tr>
<td>3. A recent high-quality systematic review or other evidence review is not available on this topic</td>
<td>Yes. We did not find any systematic reviews to address the key questions.</td>
</tr>
<tr>
<td>4. Impact of a New Evidence Review</td>
<td></td>
</tr>
<tr>
<td>4a. Is the standard of care unclear (guidelines not available or guidelines inconsistent, indicating an information gap that may be addressed by a new evidence review)?</td>
<td>Yes. The impact of PA for post-acute care is not known.</td>
</tr>
<tr>
<td>4b. Is there practice variation (guideline inconsistent with current practice, indicating a potential implementation gap and not best addressed by a new evidence review)?</td>
<td>Yes. The impact of PA for post-acute care is not known.</td>
</tr>
<tr>
<td>5. Primary Research</td>
<td></td>
</tr>
<tr>
<td>5. Effectively utilizes existing research and knowledge by considering:</td>
<td>We did not find any primary studies to address the nomination.</td>
</tr>
<tr>
<td>- Adequacy (type and volume) of research for conducting a systematic review</td>
<td></td>
</tr>
<tr>
<td>- Newly available evidence (particularly for updates or new technologies)</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** AMA=American Medical Foundation.